ATTORNEY DOCKET No.: 0079571-0110 (BU04-17 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

J. Porco, et al.

Examiner:

To be assigned

Serial No.:

10/593,502

Group Art Unit:

To be assigned

Filing Date:

September 20, 2006

Title:

Synthesis of Rocaglamide Natural Products via Photochemical Generation of

Oxidopyrylium Species

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Form PTO-1449 (4 pages);
- 2. Information Disclosure Statement (6 pages);
- Cited Art (45); and 3.
- 4. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721

Respectfully submitted,

Dated: May 22, 2007

Brenda Herschbach Jarrell, Ph.D.

Registration No. 39,223

CHOATE, HALL & STEWART LLP

Patent Department Two International Place Boston, MA 02110

Tel: 617-248-5000

Fax: 617-248-4000

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Pox 1450, Alexandria, VA 22313-1450.

May 22, 2007

Date

Signature

Elaine Cruz

Typed or Printed Name of person signing certificate

MAY 2 5 2007 W

ATTORNEY DOCKET No.: 0079571-0110 (BU04-17 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

J. Porco, et al.

Examiner:

To be assigned

Serial No.:

10/593,502

Group Art Unit:

To be assigned

Filing Date:

September 20, 2006

Title:

Synthesis of Rocaglamide Natural Products via Photochemical Generation of

Oxidopyrylium Species

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

I certify that this correspondence is bei as First Class Mail in an envelope addr	Certificate of Mailing ing deposited with the United States Postal Service with sufficient postag ressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450. May 22, 2007	Harranno
Date	Signature Elaine Cruz
Typed o	r Printed Name of person signing certificate

Sir:

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

U.S.S.N.: 10/593,502

The present Information Disclosure Statement is:

[X] An *original* Information Disclosure Statement; or

[] A supplemental Information Disclosure Statement.

Page 1 of 6

Attorney Docket No.: 0079571-0110

Customer No.: 24280

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

[X]	Pursu	ant to 3	7 CFR § 1.97(b); no fee or certification is required:
	[]	Withi	in three months of the filing date of a national application other than
		a con	tinued prosecution application under § 1.53(d);
	[]	Withi	in three months of the date of entry of the national stage as set forth
		in § 1	.491 in an international application;
	[X]	Befor	e the mailing of a first Office action on the merits; or
	[]	Befor	e the mailing of a first Office action after the filing of a request for
		contin	nued examination under § 1.114.
[]	Pursu	ant to 3	7 CFR § 1.97(c) after the dates listed above but before the mailing
	date o	of any o	f a final action under § 1.113, a notice of allowance under § 1.311, or
	an act	tion that	t otherwise closes prosecution in the application; Applicant hereby
	either	·:	
	[]	Certif	ies that either:
		[]	each item of information contained in the information disclosure
			statement was first cited in any communication from a foreign
			patent office in a counterpart foreign application not more than
			three months prior to the filing of the information disclosure
			statement; or
		[]	That no item of information contained in the information
			disclosure statement was cited in a communication from a foreign
			patent office in a counterpart foreign application, and, to the

Attorney Docket No.: 0079571-0110 Customer No.: 24280

U.S.S.N.: 10/593,502

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

	[]	Includes herewith the fee set forth in § 1.17(p).
[]	Pursu	ant to 37 CFR § 1.97(d), after the mailing date of any of a final action under
	§ 1.1	13, a notice of allowance under § 1.311, or an action that otherwise closes
	prose	ecution in the application; Applicant hereby both:

[] Certifies that *either*:

- each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [X] A copy of each cited reference not indicated with a * is included;
- Copies of references indicated with a † on the attached form PTO-1449

 are not included pursuant to 37 CFR § 1.98(d) because they were previously

 provided/cited to the United States Patent Office in an Information Disclosure

 Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the

 following patent application that is relied upon in the present case for an earlier

 effective filing date under 35 USC § 120:
- [] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the aboveidentified application:

Applicant certifies that the Information Disclosure Statement either:

- [X] Does not contain non-English language citations;
- [] Does contain non-English language citations, of which an English language translation of the Abstract for each is provided herein:
- [] Includes one or more translations of a non-English citation.

Page 4 of 6
Attorney Docket No.: 0079571-0110

Customer No.: 24280

Remarks

The submission of this Information Disclosure Statement should not be construed as a

representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an

admission that the information cited in the statement is, or is considered to be, material to

patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a

representation that the information cited in the Statement is, or is considered to be, in fact, prior

art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other

information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the

cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark

Office during the examination of this application; and

3. The citations for the patent(s) and publication(s) be printed on any patent which

issues from this application.

U.S.S.N.: 10/593,502

Page 5 of 6

Attorney Docket No.: 0079571-0110

Customer No.: 24280

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: May 22, 2007

Brenda Herschbach Jarrell, Ph.D.

Registration No. 39,223

CHOATE, HALL & STEWART, LLP PATENT GROUP Two International Place Boston, MA 02110

Tel: 617-248-5000 Fax: 617-248-4000

U.S.S.N.: 10/593,502

	/ 6156		1		
Form PTO-144 (REV. 8-83)	N 1	partment of Commerce and Trademark Office	Attorney Docket 0079571-0110	In re App 10/593,50	olication No. 02
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			Applicant:	 	
INFORM	MINON DISCLOSUI	RE STATEMENT	Porco, et al.		
	(Use several sheets if n	ecessary)	Filing Date:	Group:	
			September 20, 2006	NYA	
IIC DATENT	DOCUMENTS			1	
	T	1 ·		Tai	
Examiner's	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
Initials					
U.S. PATENT	APPLICATIONS				
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:
FOREIGN PA	TENT DOCUMENTS				
Examiner's	Document No.	Country	International	Translation	
Initials			Publication Date	Yes	No
OTHER DOC	UMENTS				
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)				
·	Bacher et al., "Thapsakins: possible biogenetic intermediates towards insecticidal cyclopenta[b]benzofurans from Aglaia edulis", Phytochemistry, 1999, 52: 253-263				
•	Bader et al., "Proton transfer in 3-hydroxylavone studied by high-resolution 10 K laser-excited Shpol'skii spectroscopy", J. Phys. Chem. A, 2002, 106: 2844-2849				
	Baer, "Oxidative Cleavage of α-Keto Acids and α-Keto Alcohols by Means of Lead Tetraacetate", J. Chem. Soc., 1940, 62: 1597-1606				
	Baldwin et al., "Expedient synthesis of a highly substituted tropolone via a 3-oxidopyrylium [5+2] cycloaddition reaction", Tetrahedron Lett., 2003; 44: 4543-4545				rylium
	Baumann et al., "Inducible Expression and Phosphorylation of Coactivator BOB.1/OBF.1 in T Cells", J. Biol. Chem., 2002, 277: 44791-44800				BF.1 in T
Bohnenstengel et al., "Structure activity relationships of antiproliferative rocaglamide derivatives from Aglaia species (Meliaceae)", Z. Naturforsch. [C], 1999, 54: 55-60					
Bohnenstengel et al., "1H-cyclopenta[b]benzofuran lignans from Aglaia species inhibit cell proliferation and alter cell cycle distribution in human monocytic leukemia cell lines", Z. Naturforsch. [C], 1999, 54: 1075-1083				i	
	Chou, "The host/guest type of excited-state proton transfer: a general review", J. Chin. Chem. Soc., 2001, 48: 651-682				n. Chem.
	Cui et al., "Novel Cytotoxic 1H-Cyclopenta[b]Benzofuran Lignans from Aglaia Elliptica", Tetrahedron, 1997, 53: 17625-17632				itica",
	Crout and Rathbone, "Catalysis Di-n-butyltin Oxide of a Tertiary Ketol Rearrangement:				

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket 0079571-0110	In re Application No. 10/593,502	
	ATION DISCLOSURE STATEMENT	Applicant: Porco, et al.		
(1)	Ise several sheets if necessary)	Filing Date: September 20, 2006	Group: NYA	
	Synthesis of Intermediates and Analogues of Va Chem. Commun., 1987 , 290-291	line and Isoleucine Biosyr	thesis", J. Chem. Soc.	
	Creary et al., "Diels-Alder approach to bicyclic rearrangements of strained .alphahydroxy ketor			
	Dumontet <i>et al.</i> , "New nitrogenous and aromatic forbesii", <i>Tetrahedron</i> , 1996 , 52: 6931-6942	derivatives from Aglaia a	rgentwa and A.	
	Fahrig et al., "A Synthetic Derivative of the Natural Product Rocaglaol Is a Potent Inhibitor of Cytokine-Mediated Signaling and Shows Neuroprotective Activity in Vitro and in Animal Models of Parkinson's Disease and Traumatic Brain Injury", Mol. Pharmacol., 2005, 67: 1544-1555.			
1	Gerard <i>et al.</i> , "A Biomimetic Approach to the Rooxidopyryliums Derived from 3-Hydroxyflavon		-	
	Hailes et al., "A biomimetic approach to the synthesis of rocaglamide based on a photochemical [2+2] cycloaddition of a cinnamate unit to a flavone", Tetrahedron Lett., 1993, 34: 5313-5316			
	Hausott et al., "Flavaglines: A group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells", Int. J. Cancer, 2004, 109: 933-940			
· 1	Hendrickson and Farina, "A new 7-ring cycloaddition reaction", J. Org. Chem., 1980, 45: 3359-3361			
	Hwang et al., "Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives from Aglaia silvestris", J. Org. Chem., 2004, 69: 3350-3358			
	Itoh, "Fluorescence studies of the excited-state phydroxychromones in supersonic jet", Pure and			
	Ishibashi et al., "Insecticidal 1H-Cyclopentatetra Phytochemistry, 1993 , 32: 307-310	hydro[b]Benzofurans fror	n Aglaia Odorata",	
· · · · · · · · · · · · · · · · · · ·	Kasha, "Proton-transfer spectroscopy. Perturbati Soc. Faraday Trans. 2, 1986, 82: 2379-2392	on of the tautomerization	potential", J. Chem.	
	King <i>et al.</i> , "X-Ray Crystal Structure of Rocagla Cyclopenta[b]benzofuran from Aglaia elliptifolia 1151	•	i	
1	Klymchenko et al., "3-Hydroxychromone dyes e transfer in water with efficient two-band fluoresc	•		
1	Klymchenko, "Elimination of hydrogen bonding hydroxyflavones", <i>J. Phys. Chem. A</i> , 2003 , 107:		n of 3-	
,	Kraus and Sy, "A synthetic approach to rocaglan nitriles", J. Org. Chem., 1989, 54: 77-83	nide via reductive cyclizat	ion of .deltaketo	
	Kumar et al., "Intramolecular excited-state proto environments", Spectrochim. Acta, Part A, 2001		ones in different	

(REV. 8-83)	Patent and Trademark Office	Aπorney Docket 0079571-0110	10/593,502		
		Applicant:			
	IATION DISCLOSURE STATEMENT	Porco, et al.			
((Use several sheets if necessary)	Filing Date:	Group:		
		September 20, 2006	NYA		
	Laermer et al., "Femtosecond spectroscopy of exhydroxyphenyl)benzothiazole", Chem. Phys. Lei		r in 2-(2'-		
	Lee et al., "Cytostatic mechanism and antitumor lignans isolated from Aglaia elliptica", Chem. B.				
	Lee and Wu, "Total Synthesis of Kaempferol an Chem. Soc., 2001, 48: 201-206	d Methylated Kaempferol	Derivatives", J. Chin.		
	Lui et al., "A general protocol for the hydroxyla hydroxy-GA ₁ methyl ester", Tetrahedron, 1998,	_	s: synthesis of 14β-		
	Mandal et al., "Evidence of ground-state proton- alcoholic solvents", J. Phys. Chem. A, 2003; 10		roxyflavone in neutral		
	Matsuura and Takemo, "Photoinduced reactions. 61. Photorearrangement of 3-hydroxyflavones to 3-aryl-3-hydroxy-1,2-indandiones", <i>Tetrahedron</i> , 1973 , 3337-3340				
	Ohse et al., "Cyclopentabenzofuran Lignan Prot Nat. Prod., 1996, 650-652	ein Synthesis Inhibitors fro	om Aglaia odorata", J.		
	Paquette and Hofferberth, "Effect of 9,10-cyclic acetal sterochemistry on feasible operation of the alpha-ketol rearrangement in highly functionalized paclitaxel (Taxol) precursors", J. Org. Chem., 2003, 68: 2266-2275				
	Proksch et al., "Chemistry and biological activit compounds in Aglaia species (Meliaceae)", Curr	•			
	Piers et al., "Sequential anionic 1,3-ester shifts and intramolecular stille couplings: a new protocol for the concise assembly of functionalized polycyclic dienes", Synlett., 1999, 7: 1082-1084				
	Roschal et al., "Flavonols and Crown-Flavonols of Ba ²⁺ and Mg ²⁺ Complexes", J. Phys. Chem. A		s. The Different Nature		
	Sammes et al., "The preparation and some reaction Trans. I, 1983, 1261-1265	ions of 3-oxidopyrylium",	J. Chem. Soc. Perkin		
	Schwartz et al., "Direct observation of fast proton transfer: femtosecond photophysics of 3-hydroxyflavone", J. Phys. Chem., 1992, 96: 3591-3598				
	Shipman et al., "Synthesis of 1,3,2-dioxathiolanequivalents", Tetrahedron, 1999, 55: 10845-108	•	otential allene oxide		
	Tamaki <i>et al.</i> , "Syntheses of (–)-(7S)- and (+)-(7379-382	R)-K252a dimers", Tetrai	hedron Lett., 2002 , 43:		
	Tanaka et al., "Synthesis of flavonol derivatives Lett., 2000, 41: 9735-9739	as probes of biological pro	ocesses", Tetrahedron		
	Trost et al., "An unusual oxidative cyclization. A assignment of (-)-rocaglamide", J. Am. Chem. So	•			
	Wender et al., "The First Synthesis of a Daphna	ne Diterpene: The Enantio	controlled Total		

Form PTO-144 (REV. 8-83)	9 U.S. Department of Commerce Patent and Trademark Office	Attorney Docket 0079571-0110		In re Application No. 10/593,502	
INFORM	IATION DISCLOSURE STATEMENT	Applicant: Porco, et al.			
(Use several sheets if necessary)		Filing Date: September 20, 2006		Group: NYA	
Synthesis of (+)-Resiniferatoxin", J. Am. Chem. Soc., 1997, 119: 12976-12977				12977	
Wu et al., "Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia", J. λ Prod., 1997, 60: 606-608			elliptifolia", J. Nat.		
EXAMINER			DATE CONSID	ERED	
	itial if citation considered, whether or not citation for not in conformance and not considered. Include			•	

4 of 4

Attorney Docket No.:0079571-0110 Client Reference No.: BU04-17 Customer No.: 24280